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OBJECTIVES: The objectives of this study are to examine socio-demographic and 
clinical characteristics of patients with rheumatoid arthritis(RA) and to estimate 
productivity costs related to RA using data from the Fourth Korea National Health 
and Nutrition Examination Survey conducted in 2007(KNHANES IV-1) and 
2008(KNHANES IV-2). METHODS: A total of 7559 adults of working age(19 ≤ age 
<65) were available for analyses, including 99 individuals with RA. Socio-demo-
graphic and clinical characteristics of subjects with RA were compared with those of 
subjects without RA. Multiple logistic regression was used to estimate adjusted 
employment rates of RA population. Percentage of work disability due to RA was 
estimated using the difference between employment rates of general population 
without RA and the adjusted employment rates of RA population. All statistical 
analyses were performed with SURVEY procedure of SAS/STAT® 9.1. RESULTS: The 
mean age of patients with RA was 50.2 years and 73.0% of them were female. Indi-
viduals with RA were older and had lower rates of subjective health awareness, higher 
rates of activity limitation and lower employment rates than individuals without RA. 
The percentage of sick leave due to RA was 2.5%. According to the results of multiple 
logistic regression, subjects with RA were less likely to be employed than subjects 
without RA (OR 0.63, 95% CI 0.41–0.97). The estimated percentage of work dis-
ability due to RA was 11.1%. By using the human capital approach, per capita pro-
ductivity costs due to work disability were estimated to 3.6 million won($3594) per 
year. CONCLUSIONS: In South Korea, the percentages of work disability and sick 
leave for RA patients were lower than those reported in previous studies. Although 
other aspects of productivity costs related to RA could not be analyzed, this study 
could provide several important results concerning productivity costs in patients with 
RA. 
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OBJECTIVES: To compare dosing proﬁ les between duloxetine and pregabalin among 
patients with ﬁ bromyalgia. METHODS: A retrospective cohort study was conducted 
on a large U.S. administrative claims database to examine commercially insured 
individuals aged 18 to 64 who had ﬁ bromyalgia and initiated (a 90-day clean period 
before initiation) duloxetine or pregabalin in 2007. Continuous enrollment in the 12 
months pre- and post-index periods and at least 30-day supply of duloxetine or pre-
gabalin over the 1-year follow-up were required for all selected patients. Average daily 
doses of all duloxetine or pregabalin prescriptions per person, average daily dose and 
average daily costs in each of the ﬁ rst 12 prescriptions, percent of patients with 
increased or decreased dose, and percent of daily dose change from previous prescrip-
tion were compared between duloxetine and pregabalin cohorts. RESULTS: Both the 
duloxetine (n = 1699) and pregabalin (n = 2560) cohorts had a mean age of 51~52 
years. Duloxetine-treated patients had an average initial daily dose of 55.6 mg versus 
159.8 mg for the pregabalin-treated patients. The average daily dose per patient was 
55.7 mg for duloxetine and 195.4 mg for pregabalin. The average duloxetine daily 
doses and daily costs ranged from 55.0 mg–60.2 mg and $3.9-$5.0 for the ﬁ rst 12 
prescriptions and 159.8 mg–265.7 mg and $4.4–$5.0 for pregabalin. The percentages 
of daily-dose changes from previous prescription were −5.4%~3.0% for duloxetine 
and −1.0%~16.6% for pregabalin. Over the 1-year follow-up, both the percentages 
of patients with a dose increase (17.3% for duloxetine vs. 51.8% for pregabalin, P < 
0.01) and a dose decrease (24.8% for duloxetine vs. 10.0% for pregabalin P < 0.01) 
were statistically different between cohorts. CONCLUSIONS: Among patients with 
ﬁ bromyalgia, duloxetine and pregabalin initiators had very different dosing proﬁ les. 
The average daily dose for duloxetine was relatively stable over time, while pregabalin-
treated patients had signiﬁ cant dose escalation over the 12-month follow-up period.
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OBJECTIVES: To compare dosing patterns between patients with ﬁ bromyalgia who 
had high versus low duloxetine or pregabalin compliance, respectively. METHODS: 
Using a large U.S. administrative claims database, commercially insured patients aged 
18–64 who had ﬁ bromyalgia and initiated duloxetine or pregabalin in 2007 were 
examined. Medication compliance was measured via medication possession ratio 
(MPR), with MPR¡Ý (<) 0.8 as high (low) compliance. All patients selected had 
continuous enrollment in the 12-month pre- and post-index periods, at least 30 days¡− 
supply of duloxetine or pregabalin in the 12-month post-index period, and were 
classiﬁ ed into 4 mutually exclusive cohorts based on their initiation agents (duloxetine 
vs. pregabalin) and compliance levels (high vs. low). Average daily doses of the ﬁ rst 
8 prescriptions and duration between the initial dose and the ﬁ rst increased dose were 
compared across cohorts. RESULTS: Compared to the low compliance patients, 
patients with high compliance had signiﬁ cantly higher initial (duloxetine [N = 804 vs. 
895]: 56.0 mg vs. 55.2 mg; pregablin [N = 710 vs. 1,850]: 164.9 mg vs. 157.9 mg) 
and average (duloxetine: 57.0 mg vs. 54.6 mg; pregabalin: 216.8 mg vs. 187.1 mg) 
daily doses (all P < .05). The average daily doses for the ﬁ rst 8 prescriptions ranged 
from 55.0 mg–58.3 mg and 56.0 mg–60.6 mg for duloxetine high and low compli-
ance patients, respectively, while the pregabalin-treated patients had 157.9 mg–238.8 mg 
and 164.9 mg–248.3 mg, correspondingly. The duration from the initial dose to the 
ﬁ rst dose increase was 263.5 vs. 161.1 days (P < .05) for the duloxetine high versus 
low compliance patients and 268 vs. 135.4 days for the pregabalin high versus low 
compliance patients, respectively. CONCLUSIONS: Among patients with ﬁ bromyal-
gia, duloxetine and pregabalin initiators had different dosing patterns by compliance 
levels. Both duloxetine- and pregabalin-treated patients with high compliance had 
higher initial and average daily doses than those with low compliance. The average 
daily dose remained stable over time for duloxetine, however, increased for pregabalin 
for both compliance groups.
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OBJECTIVES: To test basic psychometric properties (validity, reliability and respon-
siveness) of the Greek version of the Modiﬁ ed Stanford Health Assessment Question-
naire (MHAQ) for assessment of physical disability in rheumatoid arthritis (RA). 
METHODS: The sample consisted of 120 RA patients (60.0% female, mean age 59.0) 
starting on biological antirheumatic drugs. Outcome measures were the MHAQ, the 
Disease Activity Score (DAS28) and the EQ-5D completed at baseline and at 3 months 
post-intervention. Item response frequencies and ceiling/ﬂ oor effects were examined. 
Internal consistency reliability was assessed with Cronbach’s alpha. Construct validity 
was examined by correlating baseline item and total scores of the MHAQ, with the 
EQ-5D and DAS28. MHAQ items were also tested for their correlation with the 
principal component. Effect sizes between MHAQ baseline and three-month data were 
compared to respective values for the other outcomes for evidence of responsiveness. 
RESULTS: Floor and ceiling effects for the eight MHAQ items ranged between 
0–21.7% and 0.8–4.2% respectively, and the full range of responses was used in all 
but one item. Cronbach’s alpha was 0.89 at baseline and 0.86 at three months post 
intervention, indicating good internal consistency of the instrument. Moderate correla-
tions were noted (Spearman’s ρ of 0.3 to 0.5) between most MHAQ and EQ-5D 
domains, and between the overall scores, and strong correlations (ρ > 0.5) between 
MHAQ and DAS28. Principal component analysis resulted in one factor explaining 
57.1% of the total variance of the scale and all 8 items had high correlation coefﬁ cients 
(range 0.561–0.862) with this principal component. Responsiveness was satisfactory 
as the MHAQ effect size was 0.41, comparable to EQ-5D and DAS28 effect sizes 
(0.46 and 0.33 respectively). CONCLUSIONS: Evidence has been provided to support 
the reliability, validity and sensitivity to change of the Greek version of the MHAQ 
in the evaluation of functional status of RA patients.
PMS49
PSYCHOMETRIC PROPERTIES OF THE RHEUMATOID ARTHRITIS 
DISEASE ACTIVITY INDEX (RADAI) IN A COMMUNITY POPULATION IN 
THE US
Bharmal M1, Cascade E2
1Quintiles, Rockville, MD, USA; 2iGuard, Inc, Rockville, MD, USA
OBJECTIVES: The Rheumatoid Arthritis Disease Activity Index (RADAI) was devel-
oped to provide an easy to use self-administered assessment of rheumatoid arthritis 
(RA) to complement physician assessment. This study evaluates the psychometric 
properties of a web administered version of the RADAI in a community sample in the 
US. METHODS: A random sample of iGuard.org members in the US treated with 
medications for RA completed the RADAI and a series of other questions related to 
their disease. iGuard.org is a free medication monitoring service that is introduced to 
patients through multiple sources including physician, pharmacy and online referrals. 
Internal consistency of the RADAI was evaluated using Cronbach’s alpha and item-
total correlations, and factor analysis was used to conﬁ rm the domain structure. 
Convergent validity was established using correlations with patient global assessment 
of pain and number of painful joints. RESULTS: A total of 153 RA patients completed 
the study. The mean (SD) age of respondents was 52.7 (10.9) years, 71.2% were 
females with 54.3% diagnosed with RA 1 to 5 years ago and 39.2% diagnosed 5 to 
15 years ago. The mean (SD) RADAI score was 4.59 (2.16), patient global assessment 
of pain was 52.11 (24.88) on a 100-point scale, and number of painful joints were 
7.93 (4.22). RADAI items had good internal consistency with Cronbach’s alpha of 
0.89 and all item-total correlations >= 0.56. Factor analysis conﬁ rmed one factor with 
factor loadings of all the items on the factor of >= 0.57. As expected, RADAI scores 
were signiﬁ cantly correlated with patient global assessment of pain (0.646; P < 0.0001) 
